Terumo (TRUMY)
(Delayed Data from OTC)
$17.43 USD
-0.22 (-1.25%)
Updated Jul 23, 2024 03:59 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TRUMY 17.43 -0.22(-1.25%)
Will TRUMY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TRUMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRUMY
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
Terumo (TRUMY) Moves to Strong Buy: Rationale Behind the Upgrade
TRUMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for March 28th
New Strong Buy Stocks for March 28th
Here's What Could Help Terumo Corp. (TRUMY) Maintain Its Recent Price Strength
Other News for TRUMY
MicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms
MicroVention Announces Settlement Against Former Employees for Trade Secret Misappropriation and Breach of Contract Among Other Claims
MicroVention Announces Clinical Publication of SOFAST: SOFIA™ Aspiration System as First Line Technique in Treating Acute Ischemic Stroke
MicroVention Announces the Next Evolution in Stent Innovation: MicroVention’s LVIS™ EVO™ Intraluminal Support Device Now Available in the United States
Data-Driven Growth Fuels More Upside For Overlooked Artivion